ANI Pharmaceuticals   1Q Revenues: $18.8 million (+72%) 1Q Earnings: $4.4 million (+30%) Comments: Generic sales were up 52% to $12.3 million primarily due to increased sales of EEMT, as well as Methazolamide and Etodolac products, which launched in 4Q14 and 1Q15, respectively. Branded pharmaceutical sales increased 452% to $4.3 million, driven by sales of Lithobid and Vancocin, which were acquired in 3Q14. Contract manufacturing revenue was down 26% to $1.2 million as a result of timing of cu...